Skadden advised Vaxcyte, Inc. on the approximately $1.5 billion offering of its Class A common stock and pre-funded warrants, the largest-ever biotech equity follow-on offering. Graham Robinson and Michael Hong led the Skadden team.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates